AllSci News
AB Science raises EUR 14.2m to fund masitinib Phase III, AB8939
France-based AB Science S.A. (Euronext Paris: AB) announced the completion of a EUR 14.2 million (approximately USD 15.5 million) private placement on...
Infinimmune raises USD 75m to bring IL-22 antibody into clinic
Alameda, California-based Infinimmune, a biotechnology company developing antibody therapeutics derived directly from the human immune system, has closed a...
Epicrispr raises USD 90m to advance first-in-class epigenetic therapy into pivotal FSHD studies
South San Francisco-based Epicrispr Biotechnologies has closed a USD 90 million oversubscribed Series C financing round to advance its lead epigenetic gene...
Oculis rebuilds pipeline with Privosegtor buy from Accure
Switzerland-based Oculis Holding AG (Nasdaq: OCS) has agreed to acquire all worldwide development and commercial rights to Privosegtor from Spain-based...
Avere raises USD 500m for once-weekly IL-23R challenger to Icotyde
San Francisco-based Avere Therapeutics announced a USD 500 million private placement on August 10, 2026, to fund clinical development of AVR-001 (HS-20118),...
China's Hopstem secures Series backing for iPSC neural cell therapy pipeline
China-based Hopstem Biotechnology Inc. has closed the first tranche of a Series C financing round to advance its induced pluripotent stem cell...
Johns Hopkins probes macroH2A1 splicing as biomarker for PARP, TOP1 inhibitor response
Johns Hopkins University has received a USD 1.5 million National Cancer Institute R01 renewal to investigate how epigenetic control of single-stranded DNA...
Curium continues to expand oncology PET pipeline with Abscint acquisition
Curium has completed the acquisition of Abscint SA, a Belgium-based clinical-stage radiopharmaceutical company, adding ABS-011, an investigational...
Remedium Bio's obesity gene therapy platform picks up Lilly support in USD 10m Series A
Boston-based Remedium Bio, Inc. has closed a USD 10 million Series A financing round to advance its Prometheus gene therapy platform toward first-in-human...
Aureka closes USD 100m Series B to scale biological AI foundation models for drug discovery
Laguna Hills, California-based Aureka Biotechnologies has closed a USD 100 million Series B financing round to advance its AI-native drug discovery platform...
MIT spinout Artificial Axon gets NINDS backing for MS lesion-mimicking drug screening platform
Artificial Axon Labs Inc., a Topsfield, Massachusetts-based MIT spinout, has received a USD 1.48 million SBIR R44 Phase II renewal from the National...
Velorum secures NCI grant to advance heme-targeting lung cancer therapy to IND
Velorum Therapeutics Inc., a Plano, Texas-based oncology company, has received a USD 1.26 million National Cancer Institute R44 SBIR award to advance...
Vaderis raises USD 152m to advance engasertib into Phase III HHT trial
Switzerland-based Vaderis Therapeutics AG has closed an oversubscribed USD 152 million Series B financing by private placement, simultaneously announcing...
Michigan team develops oral metabolite drug to boost anti-PD-1 therapy
Researchers at the University of Michigan have described what they said is the first microbial-metabolite-based oral drug designed to improve stem-like CD8+...
UPenn researchers document decade-long CD19 CAR T cell persistence in Nature Medicine
Researchers at the University of Pennsylvania's Abramson Cancer Center have documented functional persistence of anti-CD19 chimeric antigen receptor T cells...
The AllSci Brief
Free, systematic R&D and deal news. Daily.